JP2007244699A - Iontophoresis apparatus - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an iontophoresis apparatus which gives medicinal ions with high efficiency or at a high speed, or to provide an iontophoresis apparatus which is excellent in terms of the safety and keeps an adhesiveness and a conductivity between a non-working side electrode structure and a living skin easily in an excellent manner. <P>SOLUTION: In the iontophoresis apparatus equipped with a first electrolyte retaining part 14 for retaining an electrolysis solution, a first ion-exchange membrane 15 of a first polarity placed on the underside of the first electrolyte retaining part, and a first electrode for applying a voltage of the first polarity to the first electrolyte retaining part; a first skin contact membrane 16 made of vinylon is disposed on the underside of the first ion-exchange membrane. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to an iontophoresis device that administers a drug ion to a living body by the action of a voltage applied to a working electrode structure that holds the drug ion. The present invention relates to a tophoresis device.

  An iontophoresis device generally includes a working electrode structure that holds a chemical solution that dissociates medicinal components into positive or negative ions (drug ions), and a non-working electrode that serves as a counter electrode of the working electrode structure. The structure is provided, and the drug ions are administered into the living body by applying a voltage having the same polarity as the drug ions to the working electrode structure in a state where both the structures are in contact with the skin of the living body. .

Here, the electric charge supplied to the working electrode structure is consumed by the release of drug ions to the living body and the release of biological counter ions from the living body side to the working electrode structure side. Has a low molecular weight and thus a large amount of biological counter ions (eg, Na ⁺ , Cl ^−, etc.) with a high mobility will be mainly released, so that the transport number (the total current supplied to the working electrode structure) Among them, there is a problem in that a sufficient amount of drug cannot be administered due to a decrease in the ratio of current that contributes to the movement of drug ions.

  Patent Document 1 discloses an iontophoresis device 101 shown in FIG. 5 as a solution to such a problem.

  As shown in the figure, an iontophoresis device 101 includes an electrode 111, an electrolyte solution holding unit 112 that holds a drug solution containing drug ions disposed on the lower surface side of the electrode 111, and a lower surface side of the electrolyte solution holding unit 112. The working-side electrode structure 110 is composed of the ion exchange membrane 113 having the same polarity as the drug ions of the electrolyte solution holding unit 112.

  Moreover, the iontophoresis device 101 can also include a non-working-side electrode structure 120 including a second electrode 121 and a second electrolyte solution holding unit 122 that holds a suitable electrolyte, as necessary.

  In the iontophoresis device 101, since drug ions are administered through the ion exchange membrane 113 interposed between the drug solution holding unit 112 and the living body skin S, the release of biological counter ions is suppressed and the transport number is increased. The drug ion administration efficiency or administration rate is improved.

  In Patent Document 2, the ion exchange membrane 113 of the iontophoresis device 101 disclosed in Patent Document 1 is made of a material such as a polyolefin-based resin, a vinyl chloride-based resin, or a fluorine-based resin. It is disclosed that the dosage of a drug can be further increased by using an ion exchange membrane of a type in which a porous membrane having small pores is filled with an ion exchange resin (a resin having an ion exchange function). ing.

  Patent Document 3 discloses an iontophoresis device 201 shown in FIG.

  The iontophoresis device 201 includes a working electrode structure 210 having an electrode 211 and an electrolyte solution holding unit 212 that holds a drug solution containing drug ions, and a non-working electrode structure 220 as a counter electrode thereof. It has an electrode 221, an electrolytic solution holding unit 222 that holds the electrolytic solution, and an ion exchange membrane 223 having a polarity opposite to that of the drug ions of the electrolytic solution holding unit 212, and a voltage having the same polarity as the drug ions of the electrolytic solution holding unit 212. By applying a voltage of the opposite polarity to the electrode 221 while being applied to the electrode 211, drug ions are administered from the working electrode structure 210.

  In this iontophoresis device 201, since the energization in the non-working side electrode structure 220 is performed through the ion exchange membrane 223, the ion balance at the skin interface in the non-working side electrode structure 220 becomes good, and the skin Troubles such as inflammation and rash can be reduced or eliminated, and the safety of drug administration can be enhanced. In addition, the drug ion can be administered at a higher voltage due to the improvement in safety, so that the administration rate of the drug ion can be increased.

U.S. Pat. No. 1,391,310 JP 2004-188188 A JP 2000-288098 A

  As described above, the iontophoresis device 101 disclosed in Patent Document 2 is an iontophoresis device having the highest drug ion administration efficiency or administration speed among those known at present. Although it is conceivable, an iontophoresis device that can administer drug ions with higher efficiency or speed may be desired depending on the type of drug to be administered, the purpose of drug administration, and the like.

  In addition, the iontophoresis device 201 disclosed in Patent Document 3 can improve the safety of administration of drug ions, while maintaining good electrical conductivity from the non-working side electrode structure to the skin. There was a problem that it was difficult.

  The present invention has been made in view of the above situation, and achieves one or more of the following objects.

  That is, an object of the present invention is to provide an iontophoresis device in which drug ion administration efficiency or administration rate is remarkably increased.

  Another object of the present invention is to provide an iontophoresis device that can administer drug ions with higher efficiency or speed than the iontophoresis device described in Patent Document 2.

  Another object of the present invention is an iontophoresis device that does not easily cause inflammation or rash on the skin surface with which the non-working side electrode structure abuts, and is a close contact between the non-working side electrode structure and the living skin. It is an object of the present invention to provide an iontophoresis device capable of easily and satisfactorily maintaining the electrical property or the electrical conductivity.

  Another object of the present invention is to improve the adhesion or electrical conductivity between the non-working side electrode structure and the living skin in the iontophoresis device disclosed in Patent Document 3.

The present invention includes a first electrolyte solution holding unit that holds an electrolyte solution,
A first ion exchange membrane having a first polarity disposed on a lower surface side of the first electrolyte solution holding unit;
An iontophoresis device comprising: a first electrode for applying a first polarity voltage to the first electrolyte solution holding unit;
The above-mentioned problem is solved by an iontophoresis device (claim 1) characterized in that a first skin contact membrane made of vinylon is disposed on the lower surface side of the first ion exchange membrane.

  The vinylon used in the first skin contact film of the present invention is a synthetic resin obtained by reacting polyvinyl alcohol with formaldehyde, and the first skin contact film of the present invention is particularly preferably a fibrous vinylon. Woven or non-woven fabrics can be used.

  The film thickness of the first skin contact film of the present invention, preferably 10 to 200 μm, particularly preferably 30 to 70 μm.

  The present invention can be an iontophoresis device (first aspect) having the above configuration in the working electrode structure, and an iontophoresis device having the above configuration in the non-working electrode structure ( It is also possible to set it as a 2nd aspect.

  Specifically, the iontophoresis device of the first aspect is realized by making the electrolytic solution in the first electrolytic solution holding part a chemical solution containing drug ions of the first polarity (Claim 2).

  The iontophoresis device according to claim 2 has a configuration in which the first ion exchange membrane and the first skin contact membrane are interposed between the first electrolyte solution holding unit for holding the chemical solution and the living body skin. Even when compared with any iontophoresis device that does not include one or both of the exchange membrane and the first skin contact membrane, the administration efficiency or the administration speed of drug ions is significantly increased.

  In the iontophoresis device of the present invention, the first ion exchange membrane can be doped with drug ions of the first polarity (Claim 3), thereby further increasing the drug ion administration efficiency or rate. Can do. In addition, dope of the drug ion in this invention means the state which combined the drug ion as a counter ion of the ion exchange group in a 1st ion exchange membrane.

  In the iontophoresis device of the present invention, it is preferable that the first skin contact membrane is impregnated with a drug solution containing drug ions of the first polarity (Claim 4), and this causes an increase in competitive ions. The electrical conductivity from the first ion exchange membrane to the living skin can be improved.

  The chemical solution in the invention of claim 4 may be impregnated with a chemical solution exuded from the first electrolytic solution holding part through the first ion exchange membrane after manufacturing the iontophoresis device, or impregnated with the chemical solution in advance. It is also possible to manufacture an iontophoresis device by using the first skin contact film that has been made to occur. In the latter case, the first skin contact film can be impregnated with a chemical solution having the same composition as the chemical solution of the first electrolyte solution holding unit, or can be impregnated with a different chemical composition.

  In the invention of claim 4, it is preferable to add a thickener to the chemical liquid impregnated in the first skin contact film (claim 5), thereby improving the adhesion between the working electrode structure and the living skin. The electrical conductivity from the working electrode structure to the living body skin can be further improved.

  In invention of Claims 1-5, the 2nd electrolyte solution holding part holding electrolyte solution, the 2nd polarity 2nd ion exchange membrane arrange | positioned at the lower surface side of the said 2nd electrolyte solution holding part, and said 2nd A non-working side electrode structure further comprising a second skin contact membrane made of vinylon disposed on the lower surface side of the ion exchange membrane and a second electrode for applying a voltage to the second electrolyte solution holding part (Claim 6).

  In such an iontophoresis device, the non-working side electrode structure is energized through the second skin contact membrane composed of the second polarity second ion exchange membrane and vinylon. The effect of improving the ion balance at the interface between the structure and the skin and the effect of improving the electrical conductivity from the non-working side electrode structure to the living body skin can be achieved.

  In the invention of claim 6, it is preferable that the second skin contact membrane is impregnated with an electrolytic solution (invention 7), thereby improving the electrical conductivity from the second ion exchange membrane to the living skin. it can. In addition, the electrolyte solution of the second skin contact membrane may be impregnated with the electrolyte solution leached from the second electrolyte solution holding part through the second ion exchange membrane after manufacturing the iontophoresis device, or It is also possible to manufacture an iontophoresis device using a second skin contact membrane impregnated with an electrolyte solution in advance.

  In the invention of claim 7, it is preferable to add a thickener to the electrolytic solution impregnated in the second skin contact film (invention 8), whereby the adhesion between the non-working side electrode structure and the living body skin is preferable. The electrical conductivity from the non-working side electrode structure to the living body skin can be further improved.

  In invention of Claims 6-8, it is the 1st support which has the lower surface which counters the upper surface and the upper surface, and is arranged apart from the 1st hole which opens in the lower surface, and the 1st hole, A first support body formed with a second hole opened in the lower surface; wherein the first electrolyte solution holding part is accommodated in the first hole; and the second electrolyte solution holding part is provided in the second hole. It can be accommodated in the pores (Claim 9). In this case, the manufacture of the iontophoresis device is facilitated, the handleability is improved when the iontophoresis device is applied to a living body, etc. The effect of can be achieved.

  In the first to ninth aspects of the invention, the first electrode and / or the second electrode can be made polarizable electrodes (invention 10), whereby the first electrode and / or the second electrode Electrode reaction can be suppressed or suppressed, and safety or stability in drug ion administration can be improved.

  The iontophoresis device according to claim 9 is a second support member that has a second upper surface and a second lower surface that faces the second upper surface, and is disposed on the upper surface side of the first support member. A second support body formed with a third hole opened in the second lower surface and a fourth hole disposed apart from the third hole and opened in the second lower surface; One hole and the second hole are respectively opened on the upper surface and communicated with the third hole and the fourth hole, and polarizable electrodes are respectively connected to the third hole and the fourth hole. The iontophoresis device can be accommodated (claim 11), thereby achieving effects such as facilitation of manufacture of the iontophoresis device and improvement in handling properties when the iontophoresis device is applied to a living body. be able to.

The polarizable electrodes in the inventions of claims 10 and 11 are electrodes containing a conductor having a capacitance per unit weight of 1 F / g or more, or a conductor having a specific surface area of 10 m ² / g or more. This can increase the amount of electricity that is generated due to the formation of an electric double layer on the surface of the polarizable electrode, thereby generating gas and undesirable ions due to electrode reactions, or drug ions. It is possible to realize an iontophoresis device that can administer a larger amount of drug ions without causing alteration. Particularly preferably, the electrostatic capacitance per unit weight of the polarizable electrode can be 1 F / g or more, or the specific surface area of the polarizable electrode can be 10 m ² / g or more.

  As the conductor, it is possible to use a metal conductor such as gold, silver, aluminum, and stainless steel, or a non-metal conductor such as activated carbon or ruthenium oxide, but a non-metal conductor is used as this conductor. It is particularly preferable to reduce or eliminate the concern that metal ions are eluted from the polarizable electrode and migrate to the living body. In addition, the same effect can be acquired also when using the metal conductor by which insolubilization processing was given to the surface, such as an alumite, as a conductor which comprises a polarizable electrode.

  The polarizable electrode in the present invention can also be an electrode containing activated carbon, whereby a polarizable electrode that is inexpensive and safe and has a high capacitance can be obtained. Further, when activated carbon fiber is used as the activated carbon, an additional effect of improving the handleability of the polarizable electrode can be obtained. The activated carbon fiber can use the thing of the form of a woven fabric or a nonwoven fabric, for example.

  Specifically, the iontophoresis device according to the second aspect includes the working electrode structure including the working electrode structure and each of the configurations of claim 1, and the working side. The electrode structure includes a second electrolytic solution holding unit that holds a chemical solution containing drug ions of the second polarity, and a second electrode for applying a second polarity voltage to the second electrolytic solution holding unit ( This is realized by claim 12).

  In such an iontophoresis device, in addition to maintaining a good ion balance at the interface between the non-working side electrode structure and the living body skin, it keeps good electrical conductivity from the non-working side electrode structure to the living body skin. Therefore, it becomes possible to achieve both the safety of drug ion administration and the increase of the drug ion administration rate.

  The “drug” in the present specification has a certain medicinal effect or pharmacological action regardless of whether it is prepared or not, and treats, recovers or prevents a disease, promotes or maintains health, diagnoses a medical condition or health condition, etc. Or a substance administered to a living body for the purpose of promoting or maintaining beauty.

  The “drug ion” in the present specification means an ion that is generated by ion dissociation of a drug and is responsible for medicinal effect or pharmacological action.

  The “medical solution” in the present specification means a fluid containing drug ions, and the “chemical solution” in the present specification includes a solution obtained by dissolving a drug in a solvent such as water, or a stock solution in the case where the drug is in a liquid state. As long as at least a part of the drug is dissociated into drug ions, not only in a liquid state, but also in various states such as those in which the drug is suspended or emulsified in a solvent, or those that have been adjusted to an ointment or paste Including things.

  As used herein, “drug counter ion” means an ion present in a drug solution and having an opposite polarity to the drug ion.

  “Skin” in the present specification means a surface of a living body on which drug ions can be administered by iontophoresis, and includes, for example, the oral mucosa. “Biological body” includes humans and animals.

  The “biological counter ion” in the present specification means an ion existing on or in the living body's skin and having a polarity opposite to that of the drug ion.

  In the present specification, “lower surface side” and “upper surface side” mean the side closer to and far from the living skin on the path of the current flowing through the device when administering drug ions, respectively. Further, “lower surface” and “upper surface” of a certain member mean the lower surface side and upper surface side of the member.

  As an ion exchange membrane, an ion exchange resin formed into a film shape, a heterogeneous ion exchange membrane obtained by dispersing an ion exchange resin in a binder polymer, and forming this by heat molding or the like, A composition comprising a monomer capable of introducing an exchange group, a crosslinkable monomer, a polymerization initiator, or the like, or a resin or resin having a functional group capable of introducing an ion exchange group dissolved in a solvent is used as a cloth or mesh. Alternatively, various ion exchange membranes such as a homogeneous ion exchange membrane obtained by impregnating and filling a substrate such as a porous film and performing an ion exchange group introduction treatment after polymerization or solvent removal are known. These ion exchange membranes can be used for the ion exchange membrane of the present invention without any particular limitation.

  The cation exchange membrane in the present specification is an ion exchange membrane having a function of blocking the passage of anions while allowing passage of cations (that is, an ion exchange membrane in which cations pass more easily than anions). Specifically, Neoceptor CM-1, CM-2, CMX, CMS, CMB, etc. manufactured by Tokuyama Corporation can be exemplified.

  Similarly, an anion exchange membrane in the present specification is an ion exchange membrane having a function of blocking the passage of cations while allowing passage of anions (that is, an ion exchange membrane in which anions easily pass through cations). Specifically, an ion exchange membrane into which anion exchange groups such as Neocepta AM-1, AM-3, AMX, AHA, ACH, ACS, etc. manufactured by Tokuyama Co., Ltd. are introduced can be exemplified.

  For the ion exchange membrane of the present invention, an ion exchange membrane of a type in which pores of a porous film are filled with an ion exchange resin can be particularly preferably used. Specifically, an average pore diameter of 0.005 to 5.0 μm, more preferably 0.01 to 2.0 μm, most preferably 0.02 to 0.2 μm (based on the bubble point method (JIS K3832-1990)). 5 to 140 μm, more preferably 10 formed with a porosity of 20 to 95%, more preferably 30 to 90%, most preferably 30 to 60%. Use a porous film having a thickness of ˜120 μm, most preferably 15 to 55 μm, and ion exchange at a filling rate of 5 to 95% by weight, more preferably 10 to 90% by weight, particularly preferably 20 to 60% by weight. An ion exchange membrane filled with a resin can be used.

  The “blocking of the passage of ions” described in the present specification for an ion selective membrane or an ion exchange membrane does not necessarily mean that no ions are allowed to pass through. This includes a case where the function required for the ion selective membrane or ion exchange membrane is fully exhibited because it is sufficiently smaller than other specific ions. Similarly, “allowing the passage of ions” to describe an ion-selective membrane or an ion-exchange membrane does not mean that there are no restrictions on the passage of ions; for example, the passage of ions is restricted to some extent. Even so, it includes the case where the passage speed or amount of ions is ensured to such an extent that the functions required for the ion selective membrane or the ion exchange membrane are fully exhibited.

  FIG. 1A is an explanatory diagram showing a configuration of an iontophoresis device 1 according to an embodiment of the present invention.

  As shown in the figure, the iontophoresis device 1 mainly includes a working electrode structure 10, a non-working electrode structure 20, and a power source 40.

  The working-side electrode structure 10 holds an electrode 11 connected to one pole (first polarity pole) of the power supply 40 via a power supply line 41 and a drug solution containing drug ions having the first polarity in contact with the electrode 11. A chemical solution holding unit (electrolyte holding unit) 14, a first polarity ion exchange membrane 15 disposed on the lower surface side of the chemical solution holding unit 14, and a skin contact membrane 16 disposed on the lower surface side of the ion exchange membrane 15. The entirety is accommodated in a container or support 30a.

  On the other hand, the non-working side electrode structure 20 is connected to the other pole (second polarity pole) of the power source 40 via the power supply line 42, and the electrolyte holding that holds the electrolyte contacting the electrode 21. The part 24 is provided, and the whole is accommodated in the container thru | or support body 30b.

  Although any conductive material can be used for the electrodes 11 and 21, an active electrode using a conductive material having a lower oxidation-reduction potential than water, such as a silver / silver chloride electrode, can be used during energization. Problems such as generation of gas and undesirable ions due to electrode reactions can be reduced.

  However, since the active electrode has problems such as a reaction with a chemical solution or an electrolytic solution that progresses during storage of the apparatus, and a change in the morphology of the electrode during energization, the electrodes 11 and 21 have special characteristics by the applicant of the present application. It is particularly preferable to use a polarizable electrode (also referred to as an electric double layer capacitor (EDLC)) disclosed in Japanese Patent Application No. 2005-363085.

A polarizable electrode is an electrode having the property of energizing an electrolyte by forming an electric double layer on the surface of the electrode, and preferably contains a conductor having a capacitance per unit weight of 1 F / g or more It is possible to use a polarizable electrode, a polarizable electrode containing a conductor having a specific surface area of 10 m ² / g or more, or a polarizable electrode containing activated carbon. In this case, the capacitance of the polarizable electrode is particularly preferably 1 F / g or more, or the specific surface area of the polarizable electrode is particularly preferably 10 m ² / g or more.

As the activated carbon, it is possible to use ordinary ordinary activated carbon obtained by carbonizing and activating a raw material containing carbon such as coconut shell, wood powder, coal, pitch, coke and the like. The activated carbon preferably has a capacitance per unit weight of 1 F / g or more, or a specific surface area of 10 m ² / g or more.

  Activated carbon fibers can be used as the activated carbon contained in the polarizable electrode. In this case, an additional effect of improving the handleability of the polarizable electrode can be obtained. Activated carbon fibers can be used, for example, in the form of woven fabrics or non-woven fabrics, and in particular, carbonized novoloid fibers (fibers that have been phenolized and then cross-linked to make the molecular structure three-dimensional). When an activated material is used, it is possible to obtain a polarizable electrode having excellent handling properties, flexibility, mechanical strength (such as tensile strength) and an extremely high specific surface area and a large capacitance.

  The polarizable electrode containing activated carbon or activated carbon fiber may be composed only of activated carbon or activated carbon fiber, and other components such as a binder polymer for improving formability, shape retention, or handleability may be activated carbon or activated carbon. You may mix | blend with the fiber. Examples of the binder polymer that can be suitably used in this case include polytetrafluoroethylene or polyvinylidene fluoride. A preferable blending amount of the binder polymer with respect to 97 to 80 parts by weight of activated carbon or activated carbon fiber is 3 to 20 parts by weight.

  When a polarizable electrode is used for the electrodes 11 and 21, as shown in the figure, the electrodes 11 and 21 are arranged to pass the polarizable electrodes 11b and 21b and the polarizable electrodes 11b and 21b with a uniform current density. It can comprise from the electric bodies 11a and 21a.

  In the case of using an absorptive polarizable electrode such as activated carbon or activated carbon fiber as the polarizable electrodes 11b and 21b, it is preferable to hold a chemical solution and an electrolytic solution in the polarizable electrodes 11b and / or 21b, respectively. Thereby, the electrical conductivity in the polarizable electrode 11b and / or 21b can be improved. In this case, it is preferable to add a thickener to the chemical solution and the electrolytic solution of the polarizable electrode 11b and / or 21b, thereby improving the retention of the chemical solution and the electrolytic solution in the polarizable electrode 11b and / or 21b. it can. As a particularly preferred thickener that can be used in this case, HPC (hydroxyprogrammed pill cellulose) can be exemplified. The range of the appropriate blending amount of HPC is about 1 to 5%.

  Alternatively, it is also possible to employ an electrode containing a substance that causes an electrochemical reaction by doping or dedoping ions such as a conductive polymer disclosed in Japanese Patent Application No. 2005-229985 by the applicant of the present application. With this, it is possible to achieve the same effect as when a polarizable electrode is used. Also in this case, the electrodes 11 and 21 can be composed of the conductive polymers 11b and 21b and the current collectors 11a and 21a for energizing the conductive polymers 11b and 21b with a uniform current density.

  Further, in the case where the electrode reaction does not pose a problem due to a small amount of energization or the like, the electrodes 11 and 21 may be composed of an inert electrode such as platinum or stainless steel. In this case, a carbon electrode that can reduce the concern about elution of metal ions and migration to a living body can be particularly preferably used, and carbon is mixed into the polymer matrix disclosed in Japanese Patent Application No. 2004-317317 by the present applicant. A composite carbon electrode having a terminal member and a conductive sheet made of carbon fiber or carbon fiber paper attached to the terminal member, or a conductive sheet portion made of carbon fiber or carbon fiber paper disclosed in Japanese Patent Application No. 2005-222892 And the composite carbon electrode which has the extension part which consists of carbon fiber or carbon fiber paper, and the water repellent polymer was impregnated in a part of the extension part can be used especially preferably.

  The drug solution holding unit 14 holds a drug solution containing drug ions of the first polarity. The chemical solution holding unit 14 can be configured only with a chemical solution, but is configured by impregnating a chemical solution with a suitable absorbent carrier such as a woven or non-woven fabric of natural fibers or artificial fibers, a porous membrane, or a gel. It is also possible to do. Since the chemical solution in the chemical solution holding unit 14 is in contact with the electrode 11, in this embodiment, the voltage from the electrode 11 is directly applied to the chemical solution holding unit 14.

  Examples of the chemical solution that can be used in the chemical solution holding unit 14 in the iontophoresis device 1 having a positive first polarity include an aqueous solution of a drug in which a medicinal component such as lidocaine hydrochloride or morphine hydrochloride dissociates into positive drug ions. The drug solution in the drug solution holding unit 14 in the iontophoresis device 1 having a negative first polarity can be exemplified by an aqueous solution of a drug in which a medicinal component such as ascorbic acid dissociates into a negative drug ion.

  It is possible to mix a thickener with the chemical solution in the chemical solution holding unit 14, thereby improving the retention of the chemical solution particularly when an absorbent carrier is used. As a particularly preferred thickener that can be used in this case, HPC can be exemplified. The range of the appropriate blending amount of HPC is about 1 to 5%.

  As the ion exchange membrane 15, an ion exchange membrane having the same polarity (first polarity) as the drug ions of the drug solution holding unit 14 is used. That is, when the drug ion is a positive ion, a cation exchange membrane is used, and when the drug ion is a negative ion, an anion exchange membrane is used.

  The ion exchange membrane 15 is a type of ion exchange membrane in which the ion exchange resin is filled in the pores of a porous film made of a thermoplastic resin such as polyolefin resin, vinyl chloride resin, fluorine resin, polyamide resin, polyimide resin or the like. It can be particularly preferably used.

  The ion exchange membrane 15 can be doped with drug ions of the first polarity, which can further increase the administration efficiency or administration rate of the drug ions, and the drug ions at the start of administration of the drug ions. The rise of the administration rate of the drug can be made steeper. The ion exchange membrane 15 can be doped with the same drug ion as the drug ion of the drug solution holding unit 14, and can be doped with a drug ion different from this. The ion exchange membrane 15 can be doped with drug ions by immersing the ion exchange membrane in a chemical solution containing an appropriate concentration of drug ions for a predetermined time.

  A skin contact membrane 16 made of vinylon is disposed on the lower surface side of the ion exchange membrane 15. The skin contact film 16 can be composed of a woven or non-woven fabric of vinylon fibers having a thickness of preferably 10 to 200 μm, particularly preferably 30 to 70 μm. In this embodiment, a vinylon paper (corporation) having a thickness of 50 μm is used. Kuraray BFH No. 1) is used.

  The skin contact film 16 can be impregnated with a chemical solution containing drug ions of the first polarity, thereby further increasing the administration rate of the drug ions or increasing the administration rate at the start of administration of the drug ions. It can be steep. The chemical solution impregnated in the skin contact film 16 may have the same composition as the chemical solution in the chemical solution holding unit 14 or may have a different composition. The chemical solution may be a chemical solution that exudes from the chemical solution holding unit 14 through the ion exchange membrane 15 after the working electrode structure 10 is assembled. The skin contact membrane 16 is impregnated with a separately prepared chemical solution. Also good.

  When the skin contact film 16 is impregnated with a chemical solution, it is possible to increase the viscosity of the chemical solution by adding a thickener to the chemical solution. From this, the adhesion of the working electrode structure 10 to the living skin S can be improved. And the stability of energization can be increased. As a particularly preferred thickener that can be used in this case, HPC can be exemplified. The range of the appropriate blending amount of HPC is about 1 to 5%.

  FIG. 1B shows a configuration of a working electrode structure 10a that can be used in place of the working electrode structure 10 in the iontophoresis device 1 in a particularly preferred form.

  As shown in the figure, the working electrode structure 10a includes the same electrode 11, the chemical solution holding unit 14, the ion exchange membrane 15 and the skin contact membrane 16 as the working electrode structure 10, and the electrode 11 and An electrolytic solution holding unit 12 and an ion selective membrane 13 are provided between the chemical solution holding units 14.

  Here, the electrolyte solution holding unit 12 can hold any electrolyte solution that can ensure the conductivity from the electrode 11 to the chemical solution holding unit 14, but it can dissolve an electrolyte having a lower oxidation-reduction potential than water, or a plurality of electrolyte solutions can be used. By using a buffer electrolyte solution in which various types of electrolytes are dissolved, it is possible to suppress gas generation or ion generation due to electrode reaction during energization, or pH change due to this.

  Examples of the electrolytic solution that can achieve the above object include a 5: 1 mixed solution of 0.5 M sodium fumarate and 0.5 M polyacrylic acid.

  The electrolyte solution holding unit 12 can be constituted only by the electrolyte solution, but the electrolyte solution is impregnated with a suitable absorbent carrier such as a woven or non-woven fabric of natural or artificial fibers, a porous membrane, or a gel. It is also possible to configure.

  A thickener can be blended in the electrolyte solution of the electrolyte solution holding unit 12, and thereby, the retention property of the electrolyte solution can be enhanced particularly when an absorbent carrier is used. As a particularly preferred thickener that can be used in this case, HPC can be exemplified. The range of the appropriate blending amount of HPC is about 1 to 5%.

  For the ion selective membrane 13, a membrane-like member having a characteristic of blocking the passage of the first polar ions in the electrolyte solution holding unit 12 while allowing the drug counter ion in the drug solution holding unit 14 to pass is used. It is preferable to do.

  The ion selective membrane 13 can take the form of a semipermeable membrane (ultrafiltration membrane or the like) that allows and blocks the passage of the ions based on the molecular weight and size of ions or a three-dimensional shape. It is also possible to take the form of a charge selective membrane that allows and blocks the passage of ions based on the above. As an ion selective membrane in the form of a charge selective membrane, a second polarity ion exchange membrane can be used particularly preferably.

  When the polarizable electrode 11b is used in the electrode 11 and the polarizable electrode 11b is impregnated and held with the chemical solution, the electrolytic solution holding unit 12 is omitted.

  When the working electrode structure 10a including the ion selective membrane 13 or the electrolyte solution holding unit 12 in addition to the ion selective membrane 13 is used, undesirable ions such as hydrogen ions and hydroxyl ions are generated by the electrode reaction at the electrode 11. Even if this is the case, an additional effect is achieved in that it can be prevented from shifting to the drug solution holding part 14 or the living body interface. Further, since the drug ions can be separated from the electrode 11, the effect of preventing the drug ions from being decomposed or altered during energization is also achieved.

  In the working electrode structure 10 a, the voltage from the electrode 11 is indirectly applied to the chemical solution holding unit 14 via the electrolyte solution holding unit 12 and the ion selective membrane 13.

  The electrolyte solution holding unit 24 can hold the same electrolyte solution as the electrolyte solution holding unit 12 in the same manner.

  FIG. 1C shows the configuration of a non-working side electrode structure 20a that can be used in place of the non-working side electrode structure 20 in the iontophoresis device 1 in a particularly preferred form.

  As shown in the figure, the non-working side electrode structure 20 a includes the electrode 21 and the electrolyte solution holding unit 24 similar to those of the non-working side electrode structure 20, and also between the electrode 21 and the electrolyte solution holding unit 24. Are provided with an electrolytic solution holding unit 22 and an ion selective membrane 23, and an ion selective membrane 27 is provided on the lower surface side of the electrolytic solution holding unit 24.

  In this case, the electrolytic solution holding unit 22 can hold the same electrolytic solution as the electrolytic solution holding unit 12 in the same manner.

  The ion-selective membrane 23 is a membrane-like material having a characteristic of allowing passage of ions of the first polarity in the electrolytic solution holding unit 24 while blocking passage of ions of the second polarity in the electrolytic solution holding unit 22. It is preferable to use a member, thereby preventing undesired ions such as hydrogen ions and hydroxyl ions generated by electrolysis or the like in the electrolytic solution holding unit 22 from moving to the electrolytic solution holding unit 24 or the living body interface. Can do.

  For the ion selective membrane 27, it is preferable to use a membrane-like member having a characteristic of blocking passage of biological counter ions while allowing passage of ions of the second polarity in the electrolyte solution holding unit 24. Thus, the ion balance of the skin surface during administration of drug ions can be kept good.

  The ion selective membranes 23 and 27 can take the form of a semipermeable membrane (ultrafiltration membrane or the like) that allows and blocks the passage of the ions based on the molecular weight and size of ions or a three-dimensional shape. It is also possible to take the form of a charge selective membrane that allows and blocks the passage of the ions based on the charge. When an ion selective membrane in the form of a charge selective membrane is used, it is particularly preferable to use a first polarity ion exchange membrane for the ion selective membrane 23 and a second polarity ion exchange membrane for the ion selective membrane 27. preferable.

  The containers 30a and 30b of the working electrode structure 10 (or 10a) and the non-working electrode structure 20 (or 20a) are formed with holes that can accommodate the above-described elements, and the lower surface b is opened. It is a member formed from any material such as plastic. The containers 30a and 30b are preferably made of a flexible material that can prevent evaporation of moisture from the inside and entry of foreign matter from the outside, and can follow the movement of the living body and the unevenness of the living body skin S. The lower surface b of the containers 30a, 30b can have an adhesive layer (not shown) for enhancing the adhesion with the living skin S, and the iontophoresis device 1 is disposed on the lower surfaces of the containers 30a, 30b. A release liner (not shown), which is made of an appropriate material that can prevent evaporation of moisture and foreign matter during storage, and is removed during use can be attached.

As the power source 40, a battery, a constant voltage device, a constant current device, a constant voltage / constant current device, or the like can be used. In this embodiment, 0.01 to 1.0 mA / cm ² , preferably 0 A current adjustment is possible in the range of 0.01 to 0.5 mA / cm ² , and a constant current device that operates under a safe voltage condition of 50 V or less, preferably 30 V or less is used.

  In the iontophoresis device 1, the first polarity voltage and the second polarity voltage from the power source 40 in a state where the skin contact membrane 16 and the electrolyte solution holding unit 24 (or the ion selection membrane 27) are in contact with the living body skin S. Is applied to the electrodes 11 and 21, respectively, so that the drug ions in the drug solution holding part 14 are administered to the living body.

  In the iontophoresis device 1, since drug ions from the drug solution holding unit 14 are administered to the living body via the ion exchange membrane 15 having the same polarity as the drug ions, the amount of current consumed by the transfer of biological counter ions is reduced. The drug ion administration efficiency or administration rate can be increased.

  Further, since the skin contact film 16 made of vinylon is used as a member that comes into contact with the living body skin S, it is possible to maintain good adhesion or electrical conductivity between the skin contact film 16 and the living body skin S. Therefore, the administration efficiency or the administration rate of drug ions can be further increased.

  FIG. 2 is an explanatory diagram showing a configuration of an iontophoresis device 2 according to another embodiment of the present invention.

  The iontophoresis device 2 includes a working electrode structure 10b, a non-working electrode structure 20b, and a power supply 40 similar to that in the iontophoresis device 1, as shown in the figure.

  The working electrode structure 10b is different from the working electrode structure 10 only in that the ion exchange membrane 15 and the skin contact membrane 16 are not provided, and the electrode 11 and the chemical solution holding unit similar to the working electrode structure 10 are provided. 14 is provided.

  FIG. 2B shows a configuration of a working electrode structure 10c that can be used in place of the working electrode structure 10b in the iontophoresis device 2 in a particularly preferred form.

  As shown in the drawing, the working electrode structure 10 c includes the electrode 11 and the chemical solution holding unit 14 similar to those of the working electrode structure 10, and an additional member between the electrode 11 and the chemical solution holding unit 14. The electrolytic solution holding unit 12 and the ion selective membrane 13 are provided, and an ion selective membrane 17 as an additional member is further provided on the lower surface side of the chemical solution holding unit 14. The electrolytic solution holding unit 12, the ion selective membrane 13, and the ion selective membrane 17 can have the same configuration as the electrolytic solution holding unit 12, the ion selective membrane 13, and the ion selective membrane 23 in the iontophoresis device 1.

  When the working electrode structure 10 c is used, even if an electrode reaction occurs in the electrode 11, undesired ions such as hydrogen ions and hydroxyl ions may be transferred to the chemical solution holding unit 14. Since it can be prevented by the ion selective membrane 13, the additional effect that the safety of drug ion administration is enhanced is achieved, and further, the migration of biological counter ions to the drug solution holding unit 14 is blocked by the ion selective membrane 17. In addition, an additional effect is achieved in that the administration efficiency or rate of drug ions is increased.

  The non-working side electrode structure 20b includes the electrode 21 and the electrolyte solution holding unit 24 similar to those of the non-working side electrode structure 20, and the ion exchange membrane 25 and the skin on the lower surface side of the electrolyte solution holding unit 24. A contact film 26 is provided.

  As the ion exchange membrane 25, an ion exchange membrane having a polarity (second polarity) opposite to that of the drug ions in the drug solution holding unit 14 is used. That is, when the drug ion is a positive ion, an anion exchange membrane is used, and when the drug ion is a negative ion, a cation exchange membrane is used.

  For the ion exchange membrane 25, an ion exchange membrane of a type in which a hole in a porous film made of a thermoplastic resin such as a polyolefin resin, a vinyl chloride resin, a fluorine resin, a polyamide resin, or a polyimide resin is filled with an ion exchange resin is used. It can be particularly preferably used.

  On the lower surface side of the ion exchange membrane 25, a skin contact membrane 26 made of vinylon is disposed. The skin contact film 26 can be composed of a woven or non-woven fabric of vinylon fibers having a thickness of preferably 10 to 200 μm, particularly preferably 30 to 70 μm. In this embodiment, a vinylon paper (corporation) having a thickness of 50 μm is used. Kuraray BFH No. 1) is used.

  The skin contact film 26 can be impregnated with an electrolytic solution, thereby enhancing the conductivity of the non-working side electrode structure 20a to the living body skin. The electrolytic solution impregnated in the skin contact film 26 may have the same composition as the electrolytic solution in the electrolytic solution holding unit 24, or may have a different composition. Further, this electrolytic solution may be an electrolytic solution that exudes from the electrolytic solution holding part 24 through the ion exchange membrane 25 after the non-working side electrode structure 20a is assembled. 26 may be impregnated.

  When the skin contact membrane 26 is impregnated with the electrolytic solution, it is possible to increase the viscosity of the electrolytic solution by adding a thickener to the electrolytic solution. From this, the non-working side electrode structure 20a is applied to the living skin. Adhesion can be improved and the stability of energization can be improved. As a particularly preferred thickener that can be used in this case, HPC can be exemplified. The range of the appropriate blending amount of HPC is about 1 to 5%.

  FIG. 2C shows a configuration of a non-working side electrode structure 20c that can be used in place of the non-working side electrode structure 20b in the iontophoresis device 2 in a particularly preferred form.

  As illustrated, the non-working side electrode structure 20c includes the electrode 21, the electrolyte solution holding unit 24, the ion exchange membrane 25, and the skin contact film 26 similar to the non-working side electrode structure 20b. An electrolyte solution holding unit 22 and an ion selective membrane 23 which are additional members are provided between 21 and the electrolyte solution holding unit 24. The electrolytic solution holding unit 22 and the ion selective membrane 23 can have the same configuration as the electrolytic solution holding unit 22 and the ion selective membrane 23 in the iontophoresis device 1.

  When the non-working side electrode structure 20c is used, even if undesired ions such as hydrogen ions and hydroxyl ions are generated by the electrode reaction in the electrode 21, this is transferred to the electrolyte solution holding unit 24 or the living body interface. Therefore, the additional effect of increasing the safety of administration of drug ions is achieved.

  In the iontophoresis device 2, the first polarity voltage and the second polarity voltage from the power source 40 are respectively applied in a state where the chemical solution holding unit 14 (or the ion selection membrane 17) and the skin contact membrane 26 are in contact with the living body skin. By applying to the electrodes 11 and 21, the drug ions in the drug solution holding unit 14 are administered to the living body.

  In the iontophoresis device 1, the non-working side electrode structure 20 b (or 20 c) is energized through the ion exchange membrane 25, so that the non-working side electrode structure 20 b (or 20 c) and the biological skin S It is possible to improve the ion balance at the interface and to improve the safety of administration of drug ions by reducing inflammation and rash.

  Moreover, since the skin contact film | membrane 26 comprised by vinylon is used as a member contact | abutted to the biological skin S, it can maintain favorable adhesiveness or electricity supply between the skin contact film | membrane 26 and the biological skin S. Therefore, the administration rate of drug ions can be further increased.

  In the above-described embodiment, the skin contact film 16 is used only in the working electrode structure (iontophoresis device 1) and the skin contact film 26 is used only in the non-working electrode structure. (Iontophoresis device 2) has been described, but if the working electrode structure 10 or 10a and the non-working electrode structure 20b or 20c are combined, the working electrode structure and the non-working electrode It is possible to realize an iontophoresis device in which the skin contact films 16 and 26 are used in both of the structures, and in this case, the iontophoresis device 1 and the iontophoresis device 2 described above with respect to each of the above. The effect can be played together.

  FIG. 3 (A) is a plan view showing an iontophoresis device 3 according to still another embodiment of the present invention, and FIG. 3 (B) is a sectional view taken along the line AA.

  The iontophoresis device 3 includes a working electrode structure portion 10d composed of the same members as the working electrode structure 10 in the iontophoresis device 1, and a non-working electrode structure in the iontophoresis device 2. The non-working-side electrode structure portion 20d composed of the same member as the body 20b is used. However, in the iontophoresis device 3, by appropriately selecting the size and shape of each member, the device Improved ease of assembly and handling.

  That is, the iontophoresis device 3 includes a first electrode member 31 composed of a base 31a and a conductive pattern 31b formed on the lower surface thereof, and two holes 32a and 32b opened on the upper and lower surfaces. And a support 32.

  As shown in the figure, the conductive pattern 31b of the electrode member 31 has two circular regions and two elongated regions drawn from the circular region. Of these regions, two circular regions The regions are used as electrodes 11 and 21 for energizing a chemical solution holding unit 14 and an electrolyte solution holding unit 24 described later, respectively, and the two elongated regions connect these electrodes 11 and 21 to a power source (not shown). Are used as the power supply lines 41 and 42.

  The base 31a of the electrode member 31 can be formed of a material such as polyethylene terephthalate, and the conductive pattern 31b is formed by a coating film of a conductive paint containing conductive powder such as carbon powder, thereby forming the electrode member 31. Such costs can be reduced.

  The first support 32 is a stable material that does not change in the storage and use environment of the iontophoresis device 3, and can be formed of any material having resistance to chemicals, electrolytes, and the like, preferably It can be formed of a material such as polyurethane foam having flexibility that can follow the movement of the living body and the unevenness of the living body skin S.

  The chemical solution holding unit 14 and the electrolyte solution holding unit 24 are loaded in the holes 32 a and 32 b of the first support 32. The chemical solution holding unit 14 and the electrolytic solution holding unit 24 can have the same configuration as the chemical solution holding unit 14 and the electrolytic solution holding unit 24 in the iontophoresis devices 1 and 2, respectively.

  The first polarity ion exchange membrane 15 and the skin contact membrane 16 are disposed on the lower surface side of the chemical solution holding unit 14, and the second polarity ion exchange membrane 25 and the skin contact membrane are provided on the lower surface side of the electrolyte solution holding unit 24. 26 is arranged. The ion exchange membranes 15 and 25 and the skin contact membranes 16 and 26 can have the same configuration as the ion exchange membranes 15 and 25 and the skin contact membranes 16 and 26 in the iontophoresis devices 1 and 2, respectively.

  The method of attaching the ion exchange membranes 15 and 25 and the skin contact membranes 16 and 26 to the first support 32 is arbitrary, but as an example, the dimensions of the ion exchange membranes 15 and 25 are shown in FIG. The size of the skin contact membranes 16, 26 is larger than that of the ion exchange membranes 15, 25, and each is adhered by an adhesive layer 32 c formed on the lower surface of the first support 32. Attachment to the 1 support body 32 can be performed.

  A removable release liner (not shown) that covers the pressure-sensitive adhesive layer 32 c and the skin contact films 16 and 26 can be attached to the lower surface side of the first support 32.

  As shown in the figure, the iontophoresis device 3 stacks and integrates the electrode member 31 and the first support 32 so that the electrodes 31 and 32 and the holes 32a and 32b are aligned vertically. Manufactured.

  In the iontophoresis device 3, after the release liner is removed, the first and second skin contact films 16 and 26 are brought into contact with the living body skin S, and the same polarity as the drug ions from the power source (not shown) (Polarity) voltage is applied from the power supply line 41 to the electrode 11a, and the opposite polarity (second polarity) voltage is applied from the power supply line 42 to the electrode 21a. Is administered to the living body.

  The iontophoresis device 3 includes a skin contact membrane 16 in which the working electrode structure portion 10d is constituted by the ion exchange membrane 15 and vinylon, and the non-working side electrode structure portion 20d is constituted by the ion exchange membrane 25 and vinylon. Since the skin contact film 26 is provided, the above-described effects can be achieved with respect to each of the iontophoresis devices 1 and 2.

  Moreover, since the iontophoresis device 3 has a single flat plate (sheet shape) as a whole, it is possible to facilitate the contact operation or the application operation to the living body skin S. . Furthermore, the iontophoresis device 3 is loaded with the electrode member 31 on which the conductive pattern 31b is formed, the chemical solution holding unit 14 and the electrolyte solution holding unit 24, and the ion exchange membranes 15 and 25 and the skin contact membrane 16 on the lower surface. Since it can assemble only by laminating | stacking and integrating with the 1st support body 32 with which 26 was stuck, effects, such as the simplification of a manufacturing process and the reduction of manufacturing cost by this, can be achieved.

  FIG. 4 (A) is a plan view showing an iontophoresis device 4 according to still another embodiment of the present invention, and FIG. 4 (B) is a sectional view taken along the line AA.

  The iontophoresis device 4 includes an electrode member 31 and a first support body 32 having the same configuration as the iontophoresis device 3, and in addition, a second support body 33 and a third support body as additional members. A body 34 is provided. However, in the iontophoresis device 4, the two circular regions 11 and 21 formed by the conductive pattern 31 b of the electrode member 31 energize the polarizable electrodes 11 b and 21 b described later with a uniform current density. Functions as a current collector.

  The second support 33 has an outer dimension that is slightly smaller than that of the first support 32, and two air holes 33a and 33b that are open on the upper surface and the lower surface are formed in the left and right central portions thereof. Polarizing electrodes 11b and 21b are loaded in the holes 33a and 33b, respectively.

  The polarizable electrodes 11b and 21b can have the same configuration as the polarizable electrodes 11b and 21b described above for the iontophoresis devices 1 and 2.

  In the iontophoresis device 4, it is particularly preferable that the polarizable electrodes 11b and 21b are made of activated carbon or activated carbon fiber, and the polarizable electrodes 11b and 21b are impregnated and held with a chemical solution and an electrolytic solution, respectively. At this time, the polarizable electrode 11b can hold a chemical solution having the same composition as the chemical solution in the chemical solution holding unit 14, and the polarizable electrode 21b can have an electrolyte solution having the same composition as the electrolytic solution in the electrolytic solution holding unit 24. Can be held.

  By adding a thickener to the chemical solution and the electrolyte solution of the polarizable electrodes 11b and 21b, the retainability of the chemical solution and the electrolyte solution can be improved, and the handleability of the polarizable electrodes 11b and 21b can be improved. As a particularly preferred thickener that can be used in this case, HPC can be exemplified. The range of the appropriate blending amount of HPC is about 1 to 5%.

  A pressure-sensitive adhesive layer 33c can be formed on the lower surface of the second support 33, and the first support 32 can be integrated with the pressure-sensitive adhesive layer 33c.

  An ion selective membrane 13 having the same configuration as the ion selective membrane 13 in the iontophoresis devices 1 and 2 can be disposed as an optional member on the lower surface side of the polarizable electrode 11b.

  In the case of providing such an ion selective membrane 13, while energization from the polarizable electrode 11b to the drug solution holding part 14 is ensured by the transfer of the drug counter ion, an electrode reaction occurs in the polarizable electrode 11b. Even if undesired ions such as ions and hydroxyl ions are generated or the drug ions are altered, it is possible to prevent these ions from moving to the drug solution holding part 14 and thus to the living body interface.

  When a second polarity ion exchange membrane is used as the ion selective membrane 13, the passage of ions is allowed between the polarizable electrode 11 b and the ion selective membrane 13, and the polarizable electrode 11 b and the ion selective membrane are used. It is preferable to further dispose an isolation membrane D1 for keeping it in contact with the gas, so that it is possible to prevent the generation of gas that may be generated around the ion selective membrane 13 during energization.

  When the ion selective membrane 13 and / or the isolation membrane D1 are disposed on the lower surface side of the polarizable electrode 11b, a spacer D2 made of a polypropylene nonwoven fabric impregnated with an electrolyte is disposed on the lower surface side of the polarizable electrode 21b. By doing so, it is possible to prevent a large step from occurring between the working electrode structure portion 10d and the non-working electrode structure portion 20d.

  The ion selective film 13 and the isolation films D1 and D2 are formed on the lower surface of the second support 33 so as to be larger than the holes 33a, the ion selective film 13 and the holes 33b, respectively, as illustrated. It can attach to a 2nd support body by affixing on the adhesive layer 33c.

  The third support 34 can be formed to have the same outer dimensions as the second support. The attachment of the electrode member 31 to the second support 33 may be performed in the same manner as the attachment of the electrode member 31 to the first support 32 in the iontophoresis device 3, but the second support 33 and The electrode member 31 can be sandwiched and fixed by bonding the third support 34 with an adhesive layer (not shown) formed on the lower surface of the third support 34.

  The second and third supports 33 and 34 are stable materials that do not change in the storage and use environment of the iontophoresis device 4, and are formed of any material having resistance to chemicals, electrolytes, and the like. Preferably, it can be formed of a material such as foamed polyurethane having flexibility that can follow the movement of the living body and the unevenness of the living body skin S.

  As shown in the figure, the iontophoresis device 4 aligns the current collector 11, the holes 33a and the holes 32a in the vertical direction, and aligns the current collector 21, the holes 33b and the holes 33b in the vertical direction. Thus, it manufactures by laminating | stacking and integrating the electrode member 31 and the 1st-3rd support bodies 32-34.

  In the iontophoresis device 4, the first and second skin contact films 16 and 26 are brought into contact with the living body skin S, and a voltage having the same polarity (first polarity) as that of drug ions from a power source (not shown) is fed. By applying a voltage of the opposite polarity (second polarity) from the power supply line 41 to the current collector 21a from the power supply line 42 to the current collector 21a, the first polarity drug ions held in the drug solution holding unit 14 are applied to the living body. Be administered.

  The iontophoresis device 4 includes a skin contact membrane 16 in which the working electrode structure portion 10d is constituted by the ion exchange membrane 15 and vinylon, and the non-working side electrode structure portion 20d is constituted by the ion exchange membrane 25 and vinylon. Since the skin contact film 26 is provided, the above-described effects can be achieved with respect to each of the iontophoresis devices 1 and 2.

  Moreover, since the iontophoresis device 4 as a whole has a single plate-like (sheet-like) form, it is possible to facilitate the contact operation or the affixing operation to the living body skin S. . In addition, since the iontophoresis device 4 is additionally provided with the second and third supports 33 and 34, the dimension in the thickness direction is likely to increase as compared with the iontophoresis device 3, As shown in the drawing, by setting the outer dimensions (longitudinal direction and width direction dimensions) of the second and third supports 33 and 34 to be smaller than those of the first support 32, the flexibility of the entire device and the living skin S can be improved. It is possible to prevent the followability, stickiness, and the like from being reduced as much as possible.

Furthermore, the iontophoresis device 4
(1) Third support 34
(2) Electrode member 31 on which conductive pattern 31b is formed
(3) Second support 33 loaded with polarizable electrodes 11b and 21b
(4) The 1st support body 32 with which the chemical | medical solution holding | maintenance part 14 and the electrolyte solution holding | maintenance part 24 were loaded, and the ion exchange membranes 15 and 25 and the skin contact films | membranes 16 and 26 were stuck on the lower surface.
These four sheet-like members can be assembled by simply laminating and integrating them, so that the effects of facilitating the manufacturing process and reducing the manufacturing cost can be achieved.

  Further, since the iontophoresis device 4 is energized in the working electrode structure portion 10d and the non-working electrode structure portion 20d through the polarizable electrodes 11b and 21b, the gas generated by the electrode reaction and undesirable ions Problems such as generation can be reduced.

  As mentioned above, although this invention was demonstrated based on some embodiment, this invention is not limited to these embodiment, A various change is possible within description of a claim.

  For example, in the above embodiment, the iontophoresis device including a single working electrode structure (part) and a single non-working electrode structure (part) has been described as an example. Iontophoresis in which drug ions are administered from both of the two electrode structures by holding a drug solution containing drug ions of the opposite polarity to the drug ions in the drug solution holding unit in the electrolyte solution holding unit of the electrode structure An apparatus can be realized.

  The present invention can also be applied to an iontophoresis device in which a plurality of working electrode structures (parts) and / or non-working electrode structures (parts) are connected to a single power source. In that case, the effect of the present invention can be achieved by providing any of the electrode structures (portions) with the ion exchange membrane and the skin contact membrane according to the present invention.

  Further, as the iontophoresis device 4, the first support 32 is used as a member for storing the chemical solution holding unit 14 and the electrolyte solution holding unit 24, and the second support is used as a member for storing the polarizable electrodes 11b and 21b. 33 is used, a single support having two holes formed therein is used, the polarizable electrode 11b and the chemical solution holding part 14 are accommodated in one of the holes, and the other hole is included. The iontophoresis device substantially the same as the iontophoresis device 4 can be configured by housing the polarizable electrode 21b and the electrolyte solution holding unit 24.

  In addition, holes 32 a and 32 b in the iontophoresis device 3 are opened on the upper surface of the first support 32 for energization from the power source to the electrodes (current collectors) 11 and 21. The case where the holes 33a and 33b are opened on the upper surface of the second support 33 has been described. However, as long as it is configured so that the chemical solution holding unit 14 and the electrolyte solution holding unit 24 can be energized from a power source by some means. It is sufficient (for example, the power supply lines 41 and 42 may be formed in a needle shape, and the power supply lines 41 and 42 may be inserted from the upper surface of the closed first support body 32 or the second support body 33). The holes 32a, 32b, 33a, 33b are not necessarily opened on the upper surface.

  The shape, size, material, and the like of each member in the above embodiment are described as examples only, and the present invention is not limited to these descriptions. In addition, the drawings used for the description of the above embodiment are modified such that the dimension in the thickness direction is larger than the dimension in the width direction for easy understanding.

Explanatory drawing which shows the modification (B and C) of the structure (A) of the iontophoresis apparatus which concerns on one Embodiment of this invention, its working side electrode structure, and a non-working side electrode structure. Explanatory drawing which shows the modification (B and C) of the structure (A) of the iontophoresis apparatus which concerns on other embodiment of this invention, its working side electrode structure, and a non-working side electrode structure. The top view (A) of the iontophoresis apparatus which concerns on other embodiment of this invention, and its AA sectional drawing (B). The top view (A) of the iontophoresis apparatus which concerns on other embodiment of this invention, and its AA sectional drawing (B). Explanatory drawing which shows the structure of the conventional iontophoresis apparatus. Explanatory drawing which shows the structure of the conventional iontophoresis apparatus.

Explanation of symbols

1-4 Iontophoresis devices 10, 10a to 10c Working electrode structure 10d Working electrode structure part 11 Electrode (electrode member)
11a Electrode (current collector)
11b Polarized electrode (conductive polymer)
DESCRIPTION OF SYMBOLS 12 Electrolyte solution holding | maintenance part 13 Ion selective membrane 14 Chemical solution holding | maintenance part 15 Ion exchange membrane 16 Skin contact membrane 17 Ion selective membrane D1 Isolation membrane 20, 20a-20c Non-action side electrode structure 20d Non-action side electrode structure part 21 Electrode ( Electrode member)
21a Electrode (current collector)
21b Polarized Electrode 22 Electrolyte Holder 23 Ion Select Membrane 24 Electrolyte Holder 25 Ion Exchange Membrane 26 Skin Contact Membrane 27 Ion Select Membrane D2 Spacers 30a, 30b Support 31 Electrode Member 31a Base 31b Conductive Pattern 32 First Support 33 Second support 34 Third support 32 a, 32 b, 33 a, 33 b Hole 32 c, 33 c Adhesive layer 40 Power supply 41, 42 Feed line 101, 201 Iontophoresis device 110, 210 Working electrode structure 111, 211 Electrodes 112, 212 Electrolyte Holding Unit 112 Chemical Solution Holding Unit 113 Ion Exchange Membrane 120, 220 Non-Working Electrode Structures 121, 221 Electrodes 122, 222 Electrolyte Holding Unit 223 Ion Exchange Membrane

Claims (12)

A first electrolytic solution holding unit for holding an electrolytic solution;
A first ion exchange membrane having a first polarity disposed on a lower surface side of the first electrolyte solution holding unit;
An iontophoresis device comprising: a first electrode for applying a first polarity voltage to the first electrolyte solution holding unit;
An iontophoresis device, wherein a first skin contact membrane made of vinylon is disposed on a lower surface side of the first ion exchange membrane.   2. The iontophoresis device according to claim 1, wherein the electrolytic solution in the first electrolytic solution holding unit is a chemical solution containing drug ions having a first polarity.   The iontophoresis device according to claim 1 or 2, wherein the first ion exchange membrane is doped with drug ions having a first polarity.   The iontophoresis device according to any one of claims 1 to 3, wherein the first skin contact membrane is impregnated with a chemical solution containing a drug ion having a first polarity.   The iontophoresis device according to claim 4, wherein a thickener is blended in the chemical liquid impregnated in the first skin contact film. A second electrolyte holding unit for holding the electrolyte;
A second polarity second ion exchange membrane disposed on the lower surface side of the second electrolyte solution holding unit;
A second electrode for applying a second polarity voltage to the second electrolyte solution holding unit;
The iontophoresis device according to any one of claims 1 to 5, wherein a second skin contact membrane made of vinylon is disposed on a lower surface side of the second ion exchange membrane.   The iontophoresis device according to claim 6, wherein the second skin contact membrane is impregnated with an electrolytic solution.   8. The iontophoresis device according to claim 7, wherein a thickener is blended in the electrolytic solution impregnated in the second skin contact film. A first support having an upper surface and a lower surface facing the upper surface,
A first hole opening in the lower surface;
A first support body that is disposed apart from the first hole and formed with a second hole that opens at the lower surface;
The first electrolyte solution holding part is accommodated in the first hole;
The iontophoresis device according to any one of claims 6 to 8, wherein the second electrolyte solution holding portion is accommodated in the second hole.   The iontophoresis device according to claim 1, wherein the first electrode and / or the second electrode is a polarizable electrode. A second support having a second upper surface and a second lower surface facing the second upper surface, the second support being disposed on the upper surface side of the first support,
A third hole opening in the second lower surface;
A second support body that is disposed apart from the third hole and is formed with a fourth hole that is open on the second lower surface;
The first hole and the second hole respectively open on the upper surface and communicate with the third hole and the fourth hole;
The iontophoresis device according to claim 9, wherein polarizable electrodes are respectively accommodated in the third and fourth holes. A second electrolyte solution holding unit for holding a drug solution containing drug ions of the second polarity;
The iontophoresis device according to claim 1, further comprising a second electrode for applying a second polarity voltage to the second electrolyte solution holding unit.

Images